Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) (LUZERN)

  • STATUS
    Recruiting
  • End date
    Dec 16, 2023
  • participants needed
    23
  • sponsor
    MedSIR
Updated on 16 June 2022
estrogen
measurable disease
breast cancer
growth factor
endocrine therapy
progesterone
metastasis
carboplatin
hormone therapy
immunohistochemistry
tumor cells
epidermal growth factor receptor
HER2
EGFR
primary tumor
denosumab
human epidermal growth factor
cancer chemotherapy
bisphosphonate
progesterone receptor
fulvestrant
stage iv breast cancer
erbb2
epidermal growth factor
aromatase inhibitor
estrogen receptor
her2-negative breast cancer
BRCA1/2
BRCA1
BRCA2
RAD51
immunostimulant
mammogram
her2/neu-negative breast cancer
immunological adjuvant

Summary

This study evalues the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring either gBRCAms or gBRCAwt and HRD.

The planned number of patients is 23.

Investigational product is Niraparib 100 mg and the study dose will be 200mg or 300mg daily continuously in 28-day cycles plus aromatase Inhibitors.

Total study duration is 36 months and until 5 years of follow up.

Description

This is a Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Metastatic Breast Cancers with either Germline BRCA-mutated or Germinal BRCA-wild-type and Homologous Recombination Deficiency (HRD).

The main objetive is to assess the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring either gBRCAms or gBRCAwt and HRD.

Upon meeting all selection criteria, patients enrolled in the study will receive the combination of niraparib either 300 mg or 200 mg orally (according to baseline criteria described in Table 4), once daily, flat- fixed, continuously in 28-day cycles and AI that must be identical to the last AI-containing regimen.

A total of 23 patients will be recruited as follows:

  • Stage I: N=6 patients in the cohort A;
  • Stage II: N=8 patients in the cohort A; N=9 patients in the exploratory cohort B

The total duration of the study period is 36 months follow until 5 years of follow up.

Details
Condition Breast Cancer, Breast Cancer Metastatic
Treatment Aromatase Inhibitors, Niraparib 100 MG
Clinical Study IdentifierNCT04240106
SponsorMedSIR
Last Modified on16 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

\. Patients have been informed about the nature of study, including the exploratory sub-study and has agreed to participate and signed the informed consent prior to participation in any study- related activities
\. Male or female patients ≥ 18 years of age
\. Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1 which the Investigator believes is stable at the time of screening
\. Life expectancy ≥16 weeks
\. Patients have a histologically and/or cytologically confirmed diagnosis of breast cancer
\. Patients have radiologic evidence of inoperable locally recurrent or metastatic breast cancer (MBC) that are not candidates for curative intent
\. Patients have human epidermal growth factor receptor 2 (HER2)- negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization (ISH) test or an immunohistochemistry (IHC) status of 0, 1+, or 2+ (if IHC 2+, a negative ISH test is required) by local laboratory testing
\. Patients have hormone receptor (HR)-positive breast cancer (based on most recently analyzed biopsy) defined as estrogen receptor (ER) and/or progesterone receptor (PgR) with ≥10% of tumor cells positive for ER and/or PgR by IHC irrespective of staining intensity
\. [Cohort A]: Patients with documented germinal mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)
\. [Exploratory cohort B]: Patients with either germinal BRCA1/2 wild-type (gBRCAwt) or gBRCAms that are considered to be non- detrimental and homologous recombination deficiency (HRD) based on the HRDetect predictor test
\. [Exploratory cohort B]: Willingness and ability to provide additional six formalin-fixed paraffin-embedded (FFPE) tissue slides from the most recent tumor tissue since last progression (from either metastasis or primary tumor) to centrally perform the RAD51 assay
\. At least one and up to two prior lines of endocrine therapy (aromatase inhibitors [AIs] or fulvestrant) for treatment of locally recurrent and/or metastatic disease (except for patients progressing in the neoadjuvant or adjuvant setting)
\. Confirmed disease progression while in the last AI-containing regimen (not necessarily in the treatment line immediately prior to study entry) with secondary endocrine resistance criteria
\. Patients may have progressed on no more than one chemotherapy regimens in the metastatic setting
\. The following will not be counted as a prior line of cytotoxic chemotherapy
Prior hormonal therapy and non-hormonal targeted therapy
Targeted and biologic therapies
The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as this was started at least 5 days prior to study treatment
\. Prior carboplatin- or other platinum compound-based therapy is allowed if have
Disease-free interval > 12 months from date of completion of neoadjuvant or adjuvant treatment
been administered in one of the following settings
As potentially curative treatment for a prior non-breast cancer with no evidence of disease for ≥ 5 years
\. Patients must have evaluable or measurable disease according to Response
\. Willingness and ability to provide the most recent tumor biopsy since last progression from either metastatic or primary tissues both at the time of the inclusion and at disease progression or study termination in order to perform exploratory studies
Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1. Patient
\. Patients must agree to provide blood samples at the time of study inclusion, every three cycles of treatment, and upon disease progression or study termination in order to perform exploratory studies
with bone-only metastases are eligible
\. Adequate hematologic and organ function within 28 days before the first study treatment on Cycle 1 Day 1
\. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to study treatment and must agree to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study treatment
\. Female patients must agree not to breastfeed during the study and for 180 days after the last dose of study treatment
\. Male patients whose partners are women of childbearing potential must use a condom during niraparib therapy and for 90 days after receiving the last dose of niraparib

Exclusion Criteria

\. HER2-positive disease based on local laboratory results (performed by IHC/in situ hybridization test) or unknown HER2 status
\. Patients that are candidates for a local treatment with a radical intention
\. Patients that have previously received any PARP inhibitor (PARPi), including niraparib, in metastatic setting
\. Patients who have had radiation therapy encompassing >20% of the bone marrow within 2 weeks prior to start of treatment, excepting for palliative radiation therapy to a small field >1 week prior to Day 1 of study
\. Patients with visceral crisis who require chemotherapy
\. Patients must not be simultaneously enrolled in any interventional clinical trial and must not have received investigational therapy ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior initiating protocol therapy
\. Patients must not have a known hypersensitivity to niraparib components or excipients
\. Patients must not have received colony-stimulating factors (e.g., Granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy
\. Patients have had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy in adjuvant setting or cyclin-dependent kinases (CDK)4/6 inhibitors that persisted > 4 weeks and was related to the most recent treatment
\. Patients must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy
\. Patients must not have any known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML). 12. Patients must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
\. Patients with symptomatic uncontrolled brain metastases or leptomeningeal metastases
\. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
\. Patients who are unable to swallow orally administered medication
\. Patients must not have had diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy
\. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication
\. Female patients who are pregnant or breastfeeding, or adults of reproductive potential who are not using effective birth control methods
\. Chronic daily treatment with corticosteroids with a dose of ≥ 10 mg/day methylprednisolone equivalent (excluding inhaled steroids), except for prophylaxis use
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note